Comparison of Intravenous Lignocaine and Dexmedetomidine for Attenuation of Hemodynamic Stress Response to Laryngoscopy and Endotracheal Intubation

Deepti N. Anandani¹, Manisha S. Kapdi², Ami D. Patel³, Pratik Jain⁴

¹, ², ³, ⁴Department of Anaesthesiology, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India.

ABSTRACT

BACKGROUND
The purpose of the present study was to evaluate the efficacy of intravenous lignocaine 1.5 mg / kg & intravenous dexmedetomidine 1 mcg / kg for attenuating the haemodynamic response to laryngoscopy & endotracheal intubation in patients undergoing elective surgery under general anaesthesia.

METHODS
In this prospective randomised, comparative, clinical study, 60 patients were randomly divided into 2 groups, among them 30 patients were given infusion of 1.5 mg / kg IV lignocaine, diluted to 10 ml with normal saline, 3 minutes before intubation & 30 patients were given infusion of dexmedetomidine 1 mcg / kg diluted to 25 ml in normal saline over 10 minutes through infusion pump before induction. The heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, rate pressure product, oxygen saturation were measured at baseline, after study drug intubation at L + 1, L + 3, L + 5, L + 7 &L + 10 (L is onset of laryngoscopy). Statistical analysis was done by using descriptive & inferential statistics using chi-square test, Students paired & unpaired t test to find out the signification of the five variables namely mean heart rate (HR), mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP), mean arterial pressure (MAP) and mean rate pressure product (RPP).

RESULTS
Dexmedetomidine provided better blunting of stress response during laryngoscopy and intubation without causing clinically significant respiratory depression, bradycardia or hypotension. It is better in achieving a low RPP, which is a good predictor of myocardial oxygen consumption. Dexmedetomidine provides better cardio-protection in patients against pressor response than lignocaine.

CONCLUSIONS
In these 60 patients, dexmedetomidine (1 mcg / kg) was found to be superior to lignocaine (1.5 mg / kg) for attenuation of pressor response.

KEY WORDS
Laryngoscopy, Endotracheal Intubation, Dexmedetomidine, Lignocaine, Rate Pressure Product
Pre-treatment with dexmedetomidine attenuates haemodynamic response to laryngoscopy and intubation. The present study was undertaken to compare the efficacy of 1.5 mg / kg of IV lignocaine and 1 mcg / kg of dexmedetomidine IV infusion in attenuating the haemodynamic response to laryngoscopy and intubation.

**Objectives**
To evaluate the degree of cardiovascular response evoked by laryngoscopy and endotracheal intubation and compare the effectiveness of IV lignocaine 1.5 mg / kg and IV dexmedetomidine 1 mcg / kg as a premedication in attenuating this cardiovascular response (in terms of heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, rate pressure products, oxygen saturation (spo2) in patients undergoing elective surgeries under general anaesthesia.

**METHODS**
This was a prospective randomised, comparative, clinical study conducted from 12th February 2018 to 10th February 2019. After approval by the institutional review board (IRB) committee & written informed consent obtained from patients, 60 patients of group L and D belonging to American Society of Anesthesiologists (ASA) grade I / II who satisfied the inclusion criteria, scheduled for surgery under general anaesthesia were included in this study.

Sample size was calculated on the basis of previous studies.
1. King BD, Harris LC, Greifenstein FE et al. Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anaesthesia.
2. Gangappa RC, Channashekarappa K, Mallappa K. A clinical study of intravenous dexmedetomidine versus lignocaine premedication for attenuation of haemodynamic responses to laryngoscopy and endotracheal intubation.

**Inclusion Criteria**
- ASA grade I & II.
- Age between 20 & 60 years.
- Either sex.

**Exclusion Criteria**
- Those taking antihypertensive drugs.
- Patients with baseline HR < 60 BPM.
- History of asthma / reactive airway disease.
- Patients with cardiac, renal, hepatic, cerebral diseases.
- Obese, pregnant & nursing women.
- Patients with anticipated difficult intubation.
- Patients requiring > 1 attempt at intubation.
- Patients with history of sensitivity to drugs used in the study.
- Patients not willing to give consent.
Study Protocol

Preoperative Assessment
Detailed history, physical and systemic examination of all patients was done on the day prior to operation. Laboratory investigations like CBC, renal function tests, liver function tests, blood sugar, serum electrolytes, urine analysis, X-ray chest and electrocardiogram (ECG) were reviewed. The nature of study & procedure was explained to the patient. Written informed consent was taken from the patient.

Preoperative Preparation
All patients were kept nil by mouth at least for 6 hrs before surgery. In the operation theatre, an intravenous line was secured & pulse oximeter, non-invasive BP & ECG were attached & baseline readings were taken. All patients were premeditated with Inj. glycopyrrolate 0.004 mg / kg IV, Inj. ondansetron 0.08 mg / kg IV before preoxygenation. All patients were randomly allocated into 2 groups. Randomisation was done using computer generated random number containing in opaque sealed envelope. Each group having thirty patients.
- Group L: Infusion of plain normal saline in 25 ml over 10 minutes through infusion pump before induction & 1.5 mg / kg IV lignocaine diluted to 10 ml with normal saline 3 minutes before intubation.
- Group D: Infusion of dexmedetomidine 1 mcg / kg diluted to 25 ml in normal saline over 10 minutes through infusion pump before induction & then 10 ml normal saline 3 minutes before intubation.

All patients were preoxygenated with 100 % oxygen. Respective study drug was injected as mentioned above. Patient was induced with Inj. thiopentone sodium 6 mg / kg IV & Inj. suxamethonium 2 mg / kg IV. Patient was intubated with an endotracheal tube, maintained anesthesia with O2 (50 %), N2O (50 %), sevoflurane & Inj. Vecuronium bromide 0.08 mg / kg, HR, SBP, DBP, MAP and SPO2 were monitored & RPP was calculated. All parameters were recorded at following stages:
- Baseline
- After study drug
- At intubation
  - L + 1 (after 1 minute of laryngoscopy)
  - L + 3 (after 3 minutes of laryngoscopy)
  - L + 5 (after 5 minutes of laryngoscopy)
  - L + 7 (after 7 minutes of laryngoscopy)
  - L + 10 (after 10 minutes of laryngoscopy)

At the end of surgery, residual neuromuscular blockade was reversed with Inj. glycopyrrolate 0.008 mg / kg IV & Inj. neostigmine 0.05 mg / kg IV
Exutuation was carried out when the patient had adequately recovered from the effect of neuromuscular blockade with regular breathing pattern, good muscle tone / power, haemodynamic stability and was able to respond to verbal commands.

Statistical Analysis
Statistical analysis was done by using descriptive and inferential statistics using chi-square test, Students paired and unpaired t-test to find out the significance of the five variables namely mean heart rate, mean systolic blood pressure, mean diastolic blood pressure, mean arterial pressure and mean rate pressure product. Data analysis was carried out using Microsoft Excel spreadsheet and software online.

Table 1. Shows the age distribution of both the groups which is between 20 to 60 years with mean age of 38.3 years in lignocaine group and 39.2 years in dexmedetomidine group. Sex ratio of group lignocaine was 16 males and 14 females while that of dexmedetomidine group was 14 males and 16 females. In group L the mean weight was 56.8 kgs and in group D the mean weight was 58 kgs.

| Time          | Group L | % Change | Group D | % Change | P Value | Inference |
|---------------|---------|----------|---------|----------|---------|-----------|
| Baseline      | 86.4 ± 6.2 | -        | 88.5 ± 6.7 | -        | 0.2127  | NS        |
| After study drug | 83.4 ± 5.9 | -3.4     | 79.5 ± 6.3 | -10.1    | 0.0163  | S         |
| At intubation | 85.5 ± 4.6 | -10.9    | 81.7 ± 5.9 | -7.7     | 0.0073  | S         |
| L + 1         | 10.07 ± 8.5 | 16.6    | 89.2 ± 6.4 | 0.8      | < 0.0001 | HS        |
| L + 3         | 97.2 ± 7.6 | 12.5     | 87.0 ± 5.3 | -1.7     | < 0.0001 | HS        |
| L + 5         | 91.7 ± 6.8 | 6.1      | 80.7 ± 4.8 | -8.8     | < 0.0001 | HS        |
| L + 7         | 87.1 ± 6.6 | 0.8      | 77.0 ± 5.0 | -13.0    | < 0.0001 | HS        |
| L + 10        | 83.6 ± 5.7 | -3.2     | 74.0 ± 4.9 | -16.4    | < 0.0001 | HS        |

Table 2. Heart Rate

Positive (+) = % of rise in heart rate; negative (-) = % of fall in heart rate
Heart rate in both groups at baseline was comparable and there was no statistical difference between them (P-value > 0.05). Heart rate after infusion of study drug, during laryngoscopy and intubation in dexmedetomidine group and lignocaine group was statistically different and significant (P-value < 0.05). Heart rate at 1, 3, 5, 7 and 10 minutes after laryngoscopy in dexmedetomidine group and lignocaine group was statistically different and highly significant (P-value < 0.0001). Systolic blood pressure in both groups at baseline was comparable as there was no statistical difference between them (P-value > 0.05). After infusion of study drug, laryngoscopy and intubation at 1, 3, 5, 7 & 10 minutes DBP in the dexmedetomidine group and lignocaine group was statistically different and significant (P-value < 0.05).

Mean arterial pressure in both groups at baseline was comparable as there was no statistical difference between them (P-value > 0.05). After study drug infusion, laryngoscopy and intubation at 7% minute MAP in the dexmedetomidine group and lignocaine group was statistically different and significant (P-value < 0.05). Whereas at 1, 3, 5 and 10 minutes after laryngoscopy and intubation MAP in the dexmedetomidine group and lignocaine group was statistically different and highly significant (P-value < 0.0001).

Rate pressure product in both groups at baseline was comparable as there was no statistical difference between them (P-value > 0.05). After study drug administration, comparison of rate pressure product in dexmedetomidine

| Time         | Group L | % Change | Group D | % Change | P-Value |
|--------------|---------|----------|---------|----------|---------|
| Baseline     | 126.4 ± 8.8 | - | 127.5 ± 4.7 | - | 0.5483 |
| After study drug | 125.5 ± 6.8 | -0.7 | 120.6 ± 5.3 | -5.4 | 0.0029 |
| At intubation | 128.4 ± 5.3 | 1.6 | 1221 ± 5.0 | 4.2 | <0.0001 |
| L + 1        | 148.1 ± 5.8 | 17.2 | 1343 ± 5.5 | 5.3 | <0.0001 |
| L + 3        | 141.5 ± 6.8 | 12.0 | 1313 ± 5.1 | 3.0 | <0.0001 |
| L + 5        | 134.0 ± 6.1 | 6.0 | 1262 ± 5.2 | 1.0 | <0.0001 |
| L + 7        | 127.9 ± 6.0 | 1.2 | 1211 ± 4.5 | -5.0 | <0.0001 |
| L + 10       | 122.4 ± 6.8 | -3.2 | 1165 ± 4.0 | -8.6 | <0.0001 |

**Table 3. Systolic Blood Pressure**

| Time         | Group L | % Change | Group D | % Change | P-Value |
|--------------|---------|----------|---------|----------|---------|
| Baseline     | 78.6 ± 4.8 | - | 79.3 ± 5.1 | - | 0.5862 |
| After study drug | 73.4 ± 5.2 | -6.6 | 70.3 ± 5.0 | -11.3 | 0.0020 |
| At intubation | 77.3 ± 4.7 | -1.7 | 74.1 ± 4.3 | -6.6 | 0.0079 |
| L + 1        | 86.8 ± 5.5 | 10.4 | 81.7 ± 5.0 | 3.0 | 0.0004 |
| L + 3        | 83.6 ± 4.7 | 6.4 | 88.3 ± 4.7 | 1.2 | 0.0086 |
| L + 5        | 79.6 ± 4.8 | 1.3 | 76.3 ± 4.5 | -3.6 | 0.0003 |
| L + 7        | 76.4 ± 4.4 | -2.8 | 74.1 ± 3.7 | -6.6 | 0.0325 |
| L + 10       | 73.3 ± 4.3 | -6.7 | 70.4 ± 3.4 | -11.2 | 0.0053 |

**Table 4. Diastolic Blood Pressure**

| Time         | Group L | % Change | Group D | % Change | P Value |
|--------------|---------|----------|---------|----------|---------|
| Baseline     | 94.5 ± 5.3 | - | 95.4 ± 4.5 | - | 0.4812 |
| After study drug | 90.7 ± 4.8 | -4.0 | 87.0 ± 4.4 | -8.8 | 0.0029 |
| At intubation | 94.3 ± 4.2 | -6.2 | 90.1 ± 3.9 | -5.6 | 0.0002 |
| L + 1        | 107.2 ± 4.5 | 13.4 | 99.2 ± 4.8 | 4.0 | <0.0001 |
| L + 3        | 103.8 ± 4.3 | 9.0 | 97.3 ± 4.8 | 2.0 | <0.0001 |
| L + 5        | 97.7 ± 4.2 | 3.4 | 92.9 ± 4.2 | -2.6 | <0.0001 |
| L + 7        | 93.6 ± 4.0 | -1.0 | 89.8 ± 3.4 | -5.9 | 0.0050 |
| L + 10       | 89.7 ± 4.0 | -5.1 | 85.8 ± 3.6 | -10.0 | <0.0001 |

**Table 5. Mean Arterial Pressure**

| Time         | Group L | % Change | Group D | % Change | P-Value |
|--------------|---------|----------|---------|----------|---------|
| Baseline     | 10940 ± 1248 | - | 11270 ± 829 | - | 0.2326 |
| After study drug | 19475 ± 1045 | 0.3 | 9579 ± 774 | -15.0 | 0.0004 |
| At intubation | 10985 ± 854 | 4.5 | 9951 ± 669 | -21.5 | <0.0001 |
| L + 1        | 14914 ± 1444 | 41.9 | 11975 ± 906 | 6.3 | <0.0001 |
| L + 3        | 13760 ± 1273 | 30.9 | 11417 ± 737 | 1.3 | <0.0001 |
| L + 5        | 12294 ± 1154 | 17.0 | 10182 ± 684 | 9.6 | <0.0001 |
| L + 7        | 11145 ± 1067 | 6.0 | 9309 ± 618 | -17.4 | <0.0001 |
| L + 10       | 10244 ± 1022 | 2.5 | 8617 ± 547 | -23.5 | <0.0001 |

**Table 6. Rate Pressure Product**
group and lignocaine group was statistically different (P-value < 0.05).

During laryngoscopy and intubation and thereafter at 1, 3, 5, 7 and 10 minutes, comparison of rate pressure product in dexmedetomidine group and lignocaine group was statistically different and highly significant (P-value < 0.0001).

## DISCUSSION

Laryngoscopy & tracheal intubation are considered as the most critical events during general anaesthesia. In 1940 Reid LC, Brace et al.\(^1\) concluded that laryngoscopy & intubation increases the cardiac workload and oxygen demand of myocardium. Stoelting R.K.\(^5\) showed that the duration of laryngoscopy (less than 15 seconds) was extremely important in minimising the magnitude & duration of circulatory stimulation. Reema Goel et al.\(^4\) studied attenuation of cardiovascular response to laryngoscopy & intubation by various drugs (beta blockers like esmolol and metoprolol).

Dexmedetomidine, a selective α2 adrenoceptor agonist, causes fall in BP & HR, & sedation & analgesia. The faster its minimal respiratory depressant effect with potent sedative & analgesic effects & it's faster life that allows effective titration of drug dose.

This prospective study was conducted to know whether dexmedetomidine, a newer α 2-agonist is effective for attenuating the hemodynamic response to laryngoscopy & endotracheal intubation with the conventionally used agent lignocaine. The pre-operative HR & BP of the two groups were having no significant difference (P > 0.05). After infusion of dexmedetomidine, there was a fall in HR and BP in the study group.

### Drug and Dosage

In 1985, Stanley Tam \(^9\) concluded that 1.5 mg / kg lignocaine attenuates increase in BP & HR only when given 3 min before intubation. We used the same dosage for lignocaine in our study. In 2014, Rawal DL et al.\(^10\) did a comparative study of two different doses of dexmedetomidine (0.5 mcg / kg & 1 mcg / kg) on haemodynamic responses to induction of anaesthesia & tracheal intubation & concluded that dexmedetomidine 1 mcg / kg was more effective than 0.5 mcg / kg. We have used 1 mcg / kg of dexmedetomidine in our study.

### Patient Demographics

There was no statistically significant difference between the mean age (years) & weight (kgs) & gender distribution among both groups (P > 0.05). (Table 1)

### Hemodynamic Parameters

#### Heart Rate (Table 2)

The results in our study are as following:

- HR of both groups at baseline had no statistical difference between them (P > 0.05).

- Following administration of study drugs, there was a fall in HR in both groups, group L (-3.4 %) and group D (-10.1 %). The fall in HR reduced to (-1.0 %) in group L and to (-7.7 %) in group D during laryngoscopy & intubation. Which was statistically significant (P < 0.05).

- In L + 1, there was a maximum rise in HR from baseline in both groups, more with group L (16.6 %) than group D (0.8 %) so it was statistically highly significant (P < 0.0001).

- At L + 3, L + 5 and L + 7 HR in both groups started falling from L + 1. However, there was a rise in HR from baseline in group L (12.5 %, 6.1 % and 0.8 %) and fall from baseline in group D (-1.7 %, -8.8 % and -13.0 %) respectively which was statistically highly significant (P < 0.0001).

- At L + 10 HR in both groups was below baseline, (-3.2 %) in group L & (-16.4 %) in group D, difference was statistically highly significant (P < 0.0001).

The results of our study were similar to those carried out by-

1. Malde A et al.\(^11\) concluded that lignocaine & fentanyl both attenuated the rise in pulse rate. In our study also HR reduced after administration of lignocaine which correlates with their study.

2. Gangappa RC et al.\(^8\) A clinical study of intravenous dexmedetomidine (1 mcg / kg) versus lignocaine (1.5 mg / kg) premedication for attenuation of haemodynamic responses to laryngoscopy and endotracheal intubation. They concluded that dexmedetomidine is more effective than lignocaine.

### Systolic Blood Pressure (Table 3)

The results in our study are as following:

- SBP of both groups at baseline was comparable to each other and there was no statistical difference between them (P > 0.05).

- Following administration of study drugs, there was a fall in SBP in both groups, group L (-0.7 %) and group D (-5.4 %) and was statistically significant (P < 0.05).

- SBP increased by (1.6 %) in group L and reduced by (-4.2 %) in group D from baseline during laryngoscopy and intubation. This difference was statistically highly significant (P < 0.0001).

- In L + 1, there was a maximum rise in HR from baseline in both groups, more with group L (17.2 %) than group D (5.3 %) so it was statistically highly significant (P < 0.0001).

- At L + 3, L + 5 and L + 7 SBP in both groups started falling from L + 1. However, it was still above baseline in group L (12.0 %, 6.0 % and 1.2 %) respectively, while in group D it was above baseline at L + 3 (3.0 %) and decreased below baseline at L + 5 and L + 7 (-1.0 % and -5.0 %) respectively which was statistically highly significant (P < 0.0001) in favour of dexmedetomidine.

- AtL + 10 SBP in both groups was below baseline, (-3.2 %) in group L and (-8.6 %) in group D, difference was statistically highly significant (P < 0.0001).

The results of our study are similar to those carried out by-

1. J.M. Campbell et al.\(^12\) have shown that IV lignocaine 1.5 mg / kg offered complete attenuation against post intubation rise in HR and arterial BP when given 3 min prior to intubation.
2. Singh G et al.\textsuperscript{13} concluded that dexmedetomidine (1 mcg / kg) was more effective in blunting the SBP to laryngoscopy and endotracheal intubation as compared to lignocaine (1.5 mg / kg), which correlates with our study.

\textit{Diastolic Blood Pressure (Table 4)}

The results in our study are as follows:
- DBP of both groups at baseline was comparable to each other & there was no statistical difference between them (P > 0.05).
- Following administration of study drugs, there was a fall in DBP in both groups, group L (6.6 \%) & group D (11.3 \%). The fall in DBP reduced to (-1.7 \%) in group L & (-6.6 \%) in group D during laryngoscopy & intubation. This difference was statistically significant (P < 0.05).
- At L + 1, there was a maximum rise in SBP from baseline in both groups, more with group L (10.4 \%) than group D (3.0 \%), so it was statistically significant (P < 0.05).
- At L + 3 DBP in both groups started falling from L + 1. However, it was still above baseline in group L (6.4 \%) & in group D (1.2 \%), which was statistically significant (P < 0.05).
- At L + 5 DBP was above baseline in group L (1.3 \%) & below baseline in group D (-3.8 \%). The difference was statistically significant (P < 0.05).
- At L + 7 & L + 10 DBP in both groups was below baseline, in group L (-2.8 \% & -6.7 \%) & in group D (-6.6 \% & -11.2 \%) respectively, difference was statistically significant (P < 0.05).

The results of our study were similar to those carried out by:
1. Keniya VM et al.\textsuperscript{14} showed that 1 mcg / kg dexmedetomidine effectively attenuated the press or response to laryngoscopy & subsequent intubation, where the dexmedetomidine group was compared to the control group. After intubation, the maximal average increase was 8 \% in SBP and 11 \% in DBP, compared to 40 \% and 25 \%, respectively, in the control group, which correlates with our study.

2. Surabathuni S et al. concluded that dexmedetomidine 1 mcg / kg & lignocaine 1.5 mg / kg were effective in blunting the DBP to intubation, but dexmedetomidine was superior in blunting the haemodynamic response to laryngoscopy & endotracheal intubation, which correlates with our study.

\textit{Mean Arterial Pressure (Table 5)}

The results in our study are as following:
- MAP of both groups at baseline was comparable to each other & no statistical difference between them (P > 0.05).
- Following administration of study drug & laryngoscopy & intubation, there was a fall in MAP in both groups, group L (-4.0 \% & -0.2 \%) & group D (-8.8 \% & -5.6 \%) respectively. This difference was statistically significant (P < 0.05).
- At L + 1 & L + 3, there was a maximum rise in MAP from baseline in both groups, more with group L (13.4 \% & 9.0 \%) than group D (4.0 \% & 2.0 \%) respectively, which was statistically highly significant (P < 0.0001).
- At L + 5 MAP was still above baseline in group L (3.4 \%) & below baseline in group D (-2.6 \%), which was statistically highly significant (P < 0.0001).

- At L + 7 MAP in both groups went below baseline, in group L (-1.0 \%) & in group D (-5.9 \%), difference was statistically significant (P < 0.05).
- At L + 10 MAP in both groups was below baseline, in group L (-5.1 \%) & in group D (-10.0 \%), difference was statistically highly significant (P < 0.0001).

The results of our study were similar to those carried out by:
1. Samala S et al.\textsuperscript{15} concluded that dexmedetomidine 1 mcg / kg was superior to lignocaine 1.5 mg / kg in blunting the MAP to laryngoscopy & endotracheal intubation without any significant side effects, which correlates with our study.
2. Kalakeri et al.\textsuperscript{16} showed that dexmedetomidine (1 mcg / kg) attenuates MAP compared to basal value after drug infusion & before induction. MAP remained lower than the baseline value even after the intubation. These findings correlate with our study.

\textit{Rate Pressure Product (Table 6)}

The results in our study are as following:
- RPP of both groups at baseline was comparable to each other & no statistical difference was present between them (P > 0.05).
- Following administration of study drugs there was a fall in RPP in both groups, group L (-0.3 \%) & group D (-15.0 \%). This difference was statistically significant (P < 0.05).
- During laryngoscopy & intubation, RPP increased above baseline in group L (4.5 \%), but in group D, RPP was still below baseline (-11.5 \%). Which was statistically highly significant (P < 0.0001).
- At L + 1 & L + 3, there was a maximum rise in RPP from baseline in both groups, more with group L (41.9 \% & 30.9 \%) than group D (6.3 \% & 1.3 \%) respectively, which was statistically highly significant (P < 0.0001).
- At L + 5 & L + 7 RPP was still above baseline in group L (17.0 \% & 6.0 \%) and below baseline in group D (-9.6 \% & -17.4 \%) respectively, which was statistically highly significant (P < 0.0001).
- At L + 10 RPP in both groups was below baseline, in group L (-2.5 \%) & in group D (-23.5 \%), difference was statistically highly significant (P < 0.0001).

The result of our study was similar to those carried out by:
1. Kapdi MS et al.\textsuperscript{17} studied the comparison of dexmedetomidine (1 mcg / kg) over 10 mins through infusion pump & found that RPP decreased at 0, 1, 2, 3, 4, & 5 mins from baseline in dexmedetomidine group.
2. Sale HK et al.\textsuperscript{18} & Gangappa RC et al.\textsuperscript{19} concluded that efficacy of dexmedetomidine (1 mcg / kg) in attenuation of the pressor response to laryngoscopy & intubation compared to lignocaine (1.5 mg / kg) was significantly higher in ASA I and II patients with respect to HR, SBP, DBP and MAP, which correlates with our study.

SpO\textsubscript{2} - All patients in each group had normal arterial saturation throughout the study.

ECG: In present study no abnormal changes were recorded in any patient throughout the procedure. Burstein CL et al.\textsuperscript{19} had similar findings as compared to our study.
Dexmedetomidine provides better blunting of stress response during laryngoscopy and intubation without causing clinically significant respiratory depression, bradycardia or hypotension. It is better in achieving a low RPP, which is a good predictor of myocardial oxygen consumption. Dexmedetomidine provides better cardio-protection in patients against pressure response than lignocaine.

In conclusion, dexmedetomidine (1 mcg / kg) was found to be superior to lignocaine (1.5 mg / kg) for attenuation of pressor response.

Limitations
We did not measure the plasma catecholamine levels which is an objective means of measuring hemodynamic stress response.

Data sharing statement provided by the authors is available with the full text of this article at jemds.com.

Disclosure forms provided by the authors are available with the full text of this article at jemds.com.

REFERENCES

[1] Reid LC, Brace DE. Irritation of the respiratory tract and its reflex effect upon heart. Surg Gynecol Obstet 1940;70:157-62.
[2] King BD, Harris LC, Greifenstein FE, et al. Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anesthesia. Anesthesiology 1951;12(3):556-66.
[3] Surabathuni S, Santhilatha GR, Rao PN, et al. To evaluate the effect of intravenous dexmedetomidine (1μg/kg) as premedication in obtunding the pressor response to laryngoscopy and tracheal intubation compared to intravenous preservative free 2 % lignocaine (1.5-2mg/kg). Journal of Dental and Medical Sciences 2015;14(9):37-43.
[4] Goel R, Rani R, Singh OP, et al. Attenuation of cardiovascular responses to laryngoscopy and intubation by various drugs in normotensive patients. Hospital Today 2000;9.
[5] Stoelting RK. Blood pressure and heart rate changes during short-duration laryngoscopy for tracheal intubation: influence of viscous or intravenous lidocaine. Anesth Analg 1978;57(2):197-9.
[6] Mireskandari SM, Abulhadr N, Darabi ME, et al. Comparison of the effect of fentanyl, sufentanil, alfentanil and remifentanil on cardiovascular response to tracheal intubation in children. Iran J Pediatr 2011;21(2):173-80.
[7] Forbes AM, Daily FG. Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth 1970;42(7):618-24.
[8] Gangappa RC, Chandrashekharaappa K, Mallappa K. A clinical study of intravenous dexmedetomidine versus lignocaine premedication for attenuation of haemodynamic responses to laryngoscopy and endotracheal intubation. J Evid Based Med Healthc 2016;3(64):3470-5.
[9] Tam S, Chung F, Campbell M. Intravenous lidocaine: optimal time of injection before tracheal intubation. Anesth Analg 1987;66(10):1036-8.
[10] Raval DL, Yadav VP. A comparative study of two different doses of dexmedetomidine on haemodynamic responses to induction of anaesthesia and tracheal intubation. J Clin Exp Res 2014;2(3):163-8.
[11] Malde AD, Sareode V. Attenuation of the hemodynamic response to endotracheal intubation: fentanyl versus lignocaine. The Internet Journal of Anesthesiology 2006;12(1).
[12] Tam S, Chung F, Campbell JM. Attenuation of circulatory responses to endotracheal intubation using intravenous lidocaine—a determination of the optimal time of injection. Canadian Anaesthetists Society Journal 1985;32(3):656.
[13] Singh G, Kaur H, Aggarwal S, et al. Intravenous dexmedetomidine vs. lignocaine in attenuating the hemodynamic responses during laryngoscopy and endotracheal intubation: a randomized double blind study. Anaesthesia, Pain & Intensive Care 2019;21(2):181-6.
[14] Keniya VM, Ladi S, Naphade R. Dexmedetomidine attenuates sympathoadrenal response to tracheal intubation and reduces perioperative anaesthetic requirement. Indian J Anaesth 2011;55(4):352-7.
[15] Samala S, Indurkar PS. Effect of intravenous dexmedetomidine (1μg/kg) in obtunding the pressor response to laryngoscopy and tracheal intubation compared to intravenous preservative free 2 % lignocaine (1.5-2mg/kg). Journal of Dental and Medical Sciences 2015;14(9):37-43.
[16] Kalakeri S, Suresh C. Dexmedetomidine as an adjunct to anaesthetic induction to attenuate hemodynamic response to endotracheal intubation in patients undergoing CABG. Int J Curr Res Aca Rev 2015;3(4):101-17.
[17] Panchal M, Kapdi M, Sardhara N, et al. Comparative study of dexmedetomidine or MGSO4 to attenuate hemodynamic stress response to laryngoscopy and intubation. Indian Journal of Applied Basic Medical Sciences 2018;30(20A):1045-7.
[18] Sale HK, Shendage VJ. Lignocaine and dexmedetomidine in attenuation of pressor response to laryngoscopy and intubation: a prospective study. International Journal of Scientific Study 2015;3(9):155-60.
[19] Burstein CL, Lopinto FJ, Newman W. Electrocardiographic studies during endotracheal intubation. I. Effects during usual routine techniques. Anesthesiology 1950;11(2):224-37.